Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More

无需再手动监测血糖和频繁注射胰岛素,人造胰腺获批

2020-01-06 11:00:02 Xconomy

本文共454个字,阅读需2分钟

Recently, the US FDA approved the artificial pancreas system developed by the University of Virginia Diabetes Technology Center, which can automatically monitor and regulate the blood glucose level of patients with type 1 diabetes. It is understood that the artificial pancreas system is called Control-IQ. It can track blood glucose levels through a continuous blood glucose monitor and automatically provide insulin as needed. This eliminates the need for diabetes patients to perform daily blood glucose monitoring and frequent insulin injections. The above-mentioned clinical research results show that the Control-IQ artificial pancreas system is more effective in controlling blood glucose levels of patients with type 1 diabetes than existing treatments, and the system improves patients' blood glucose control during the day and at night. 168 patients aged 14 or older with type 1 diabetes participated in the clinical trial and were randomly assigned to use an artificial pancreas system or sensor-enhanced pump with a continuous blood glucose monitor and insulin pump, but Insulin cannot be adjusted automatically throughout the day. The researchers found that patients using the artificial pancreas system had significantly increased blood glucose levels within the target range, while the sensor-enhanced pump group's appropriate blood glucose level remained unchanged for 6 months. At the same time, compared with the sensor-enhanced pump set, users of the artificial pancreas system have also improved some diabetes control measures, including the time when hyperglycemia and hypoglycemia occur. During the study period, no severe hypoglycemia event occurred in either group.
近日,美国FDA批准了弗吉尼亚大学糖尿病技术中心研发的人造胰腺系统,该系统可以自动监测和调节1型糖尿病患者的血糖水平。 据了解,该人造胰腺系统名为Control-IQ,它可以通过一个连续血糖监测器跟踪血糖水平,并根据需要自动提供胰岛素,这让糖尿病患者不需要再每天进行血糖监测和频繁地胰岛素注射。 上述的临床研究结果显示,Control-IQ人造胰腺系统在控制1型糖尿病患者的血糖水平方面比现有的治疗方式更有效,该系统改善了患者白天和夜间的血糖控制。 有168名14岁或以上且患有1型糖尿病的患者参与了该临床试验,他们被随机地分配使用人造胰腺系统或传感器增强泵,该泵带有带有连续血糖监测仪和胰岛素泵,但不能全天自动调节胰岛素。 研究人员发现,使用人工胰腺系统的患者血糖水平在目标范围内的时间明显增加,而传感器增强泵组的适宜血糖水平在6个月内保持不变。同时,与与传感器增强泵组相比,人工胰腺系统使用者在一些糖尿病控制措施方面也有所改善,包括高血糖和低血糖发生的时间。研究期间,两组均未发生严重低血糖事件。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文